GlassScriptPhysician profile
Rama Balaraman
NPI 1396709424
$95,160.22
in general payments reported to CMS, 2019-2025
99 companies · $16K in 2025
The $16K reported for 2025 was more than what 85% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $20K · 2021: $17K · 2022: $11K · 2023: $15K · 2024: $5,717 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $11K · Travel and Lodging: $2,692 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,560 · Education: $444 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,590.00 |
| Food and Beverage | $10,658.99 |
| Travel and Lodging | $2,692.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,560.00 |
| Education | $444.48 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,559.06 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Pfizer INC. | $8,059.49 | 2019-2025 | |
| Genentech, INC. | $7,963.49 | 2023 | Venclexta |
| Alexion Pharmaceuticals, INC. | $7,250.73 | 2019-2025 | Ultomiris, Soliris |
| Foundation Medicine, INC. | $5,379.24 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,003.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $4,714.13 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,763.82 | 2019-2025 | Opdivo, Augtyro, Krazati |
| Kite Pharma, INC. | $3,667.05 | 2019-2023 | |
| Beigene USA, INC. | $3,481.54 | 2021-2025 | Brukinsa, Tevimbra |
| Pharmacosmos Therapeutics INC. | $3,216.40 | 2020-2024 | Monoferric, Cosela |
| Genentech USA, INC. | $3,052.79 | 2019-2025 | Venclexta, Tecentriq, Polivy |
| Astellas Pharma US INC | $2,652.51 | 2019-2025 | Vyloy, Padcev, Xtandi |
| Fresenius Kabi USA, LLC | $2,550.00 | 2021 | |
| Lilly USA, LLC | $2,402.98 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
Show all 97 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $1,942.37 | 2019-2023 | Onivyde |
| G1 Therapeutics, INC. | $1,577.07 | 2021-2023 | Cosela |
| Morphosys, US INC. | $1,554.33 | 2021-2023 | Monjuvi |
| Janssen Biotech, INC. | $1,303.99 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Amgen INC. | $932.67 | 2019-2024 | Nplate, Vectibix, Xgeva |
| Gilead Sciences, INC. | $924.24 | 2021-2025 | Trodelvy |
| Seagen INC. | $915.37 | 2019-2025 | Tukysa, Tivdak, Adcetris |
| Merck Sharp & Dohme LLC | $855.62 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Eisai INC. | $761.92 | 2019-2025 | |
| Daiichi Sankyo INC. | $671.06 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $617.95 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Rigel Pharmaceuticals, INC. | $543.80 | 2021-2024 | Rezlidhia, Tavalisse |
| Incyte Corporation | $540.44 | 2020-2025 | Monjuvi, Jakafi, Zynyz |
| Abbvie INC. | $537.49 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $468.00 | 2019-2025 | |
| Celltrion USA INC. | $448.57 | 2023 | Vegzelma |
| Puma Biotechnology, INC. | $335.68 | 2019-2025 | |
| Glaxosmithkline, LLC. | $329.39 | 2020-2025 | Shingrix, Jemperli, Zejula |
| Genzyme Corporation | $322.34 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $316.67 | 2019-2024 | |
| Genmab U.S., INC. | $304.66 | 2023-2025 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $284.73 | 2019-2025 | Fruzaqla, Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $258.27 | 2019-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $247.88 | 2019-2025 | Libtayo, Lynozyfic |
| Octapharma USA, INC. | $245.53 | 2020-2023 | Panzyga, Octagam Immune Globulin (Human) |
| Taiho Oncology, INC. | $224.67 | 2019-2025 | |
| Array Biopharma INC | $198.24 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Heron Therapeutics, INC. | $184.57 | 2020-2023 | Cinvanti |
| Coherus Oncology, INC. | $171.51 | 2022-2025 | Loqtorzi |
| Novocure INC. | $156.04 | 2024-2025 | Optune Lua (Novottf-200t), Optune, Optune Gio |
| Karyopharm Therapeutics INC. | $141.34 | 2021-2025 | Xpovio |
| Emd Serono, INC. | $135.71 | 2019-2025 | Bavencio |
| Beone Medicines USA, INC. | $132.41 | 2025 | Tevimbra, Brukinsa |
| Kyowa Kirin, INC. | $128.55 | 2019-2025 | Poteligeo |
| Tersera Therapeutics LLC | $128.06 | 2019-2025 | Quzyttir, Zoladex |
| Dova Pharmaceuticals | $127.75 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $126.21 | 2019-2025 | Yonsa, Odomzo |
| Servier Pharmaceuticals LLC | $125.70 | 2021-2025 | |
| Sobi, INC | $125.64 | 2023-2025 | |
| Stryker Corporation | $124.78 | 2021 | |
| Agios Pharmaceuticals, INC. | $123.02 | 2019-2025 | Pyrukynd |
| Apellis Pharmaceuticals, INC. | $122.44 | 2022-2024 | Empaveli |
| Caris Mpi, INC. | $111.41 | 2025 | Mi Cancer Seek |
| Tg Therapeutics, INC. | $110.49 | 2021-2022 | |
| Pharmaessentia USA Corporation | $106.38 | 2022-2025 | Besremi |
| Menarini Silicon Biosystems, INC. | $102.00 | 2025 | |
| Stemline Therapeutics INC. | $92.45 | 2023-2025 | Orserdu |
| Csl Behring | $89.20 | 2021-2024 | Idelvion, Afstyla |
| Tempus Ai, INC | $81.48 | 2024-2025 | Xt Cdx |
| Exelixis INC. | $81.01 | 2019-2025 | Cabometyx |
| Janssen Scientific Affairs, LLC | $76.75 | 2020-2022 | |
| Geron Corporation | $57.32 | 2024-2025 | Rytelo |
| Epizyme, INC. | $52.48 | 2020-2022 | |
| Blueprint Medicines Corporation | $49.19 | 2021-2025 | Ayvakit |
| Ge Healthcare | $49.01 | 2021-2022 | |
| Astellas Pharma Global Development | $48.30 | 2019 | |
| Mirati Therapeutics, INC. | $47.15 | 2023-2024 | Krazati |
| Adaptive Biotechnologies Corporation | $46.94 | 2025 | Clonoseq |
| Fennec Pharmaceuticals, INC. | $40.92 | 2024-2025 | Pedmark, Fyarro |
| Dendreon Pharmaceuticals LLC | $34.61 | 2025 | Provenge |
| Horizon Therapeutics Plc | $32.13 | 2019 | |
| Global Blood Therapeutics, INC. | $29.87 | 2021 | |
| Emmaus Medical, INC. | $29.46 | 2019-2022 | |
| Secura Bio, INC. | $26.25 | 2019-2024 | Copiktra |
| Lexicon Pharmaceuticals, INC. | $24.52 | 2019 | |
| Recordati_rare_diseases_inc. | $23.60 | 2023 | Sylvant |
| Immunogen, INC. | $22.90 | 2023 | Elahere |
| Springworks Therapeutics, INC. | $22.21 | 2025 | Ogsiveo |
| Adc Therapeutics America, INC. | $20.59 | 2021 | |
| Medtronic, INC. | $19.58 | 2022 | |
| Amneal Pharmaceuticals LLC | $19.02 | 2025 | Alymsys |
| Advanced Accelerator Applications | $18.97 | 2019 | |
| Clovis Oncology, INC. | $18.27 | 2019 | |
| Deciphera Pharmaceuticals INC. | $18.14 | 2025 | Romvimza, Qinlock |
| Ferring Pharmaceuticals INC. | $17.56 | 2025 | Adstiladrin |
| Cti Biopharma Corp. | $16.83 | 2023 | Vonjo |
| Alnylam Pharmaceuticals INC. | $16.69 | 2021 | |
| Blue Earth Diagnostics | $15.41 | 2021 | |
| Verity Pharmaceuticals INC. | $15.08 | 2023 | Trelstar |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2020 | |
| Acrotech Biopharma INC. | $13.80 | 2022 | |
| Aveo Pharmaceuticals, INC. | $13.53 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,746.26 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rama Balaraman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.